<- Go Home
King Pharmaceuticals Research & Development Inc.
King Pharmaceuticals Research & Development Inc. engages in the global commercialization of cardiovascular and adenosine-related products. It is a division of King Pharmaceuticals, Inc. The company’s adenosine franchise and related patented technologies complement King Pharmaceutical’s key cardiovascular portfolio, and provide it with expanded research and development capabilities. KPRD developed two marketed adenosine-based products, Adenocard, patented until 2004, and Adenoscan, patented until 2015. King Pharmaceuticals receives royalty revenues for these products. King Pharmaceuticals Research & Development Inc. operates as a subsidiary of Pfizer Inc.
Market Cap
$359.4M
Volume
32.2K
Cash and Equivalents
$4.4M
EBITDA
$15.3M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$27.7M
Profit Margin
81.37%
52 Week High
$36.00
52 Week Low
$20.50
Dividend
N/A
Price / Book Value
5.51
Price / Earnings
27.01
Price / Tangible Book Value
5.61
Enterprise Value
N/A
Enterprise Value / EBITDA
N/A
Operating Income
$14.5M
Return on Equity
22.21%
Return on Assets
13.87
Cash and Short Term Investments
$22.9M
Debt
N/A
Equity
$64.5M
Revenue
$34.1M
Unlevered FCF
$7.3M
Sector
Biotechnology
Category
N/A